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Background: Acetaminophen (APAP) hepatotoxicity is associated with a high rate of gram-negative enteric bacterial
infection; however, the underlying mechanism is still unknown. APAP overdose induces massive hepatocyte necrosis,
necrotic tissue releases high mobility group B1 (HMGB1) and exogenous HMGB1 is able to induce gut bacterial
translocation (BT) in normal mice; therefore, it is possible that HMGB1 mediates gut BT in APAP hepatotoxicity. This
study aims to test this hypothesis by using anti-HMGB1 neutralizing antibody to treat APAP overdose for 24-48 hours.
Methods: Male C57BL/6 mice were intraperitoneally (i.p.) injected with a single dose of APAP (350 mg/kg dissolved in
1 mL sterile saline). 2 hrs after APAP injection, the APAP challenged mice were randomized to receive treatment with
either anti-HMGB1 antibody (400 μg per dose) or non-immune (sham) IgG every 24 h for a total of 2 doses.
Results: 24 and 48 hrs after APAP challenge, anti-HMGB1 treatment instead of sham IgG therapy significantly decreased
serum HMGB1 concentrations and reduced BT by 85%; serum HMGB1 levels were positively correlated with the amount
of BT; anti-HMGB1 therapy decreased hepatic BT at 48 h, which was associated with better recovered liver structure
and better restored hepatic immune system that was shown by enhanced hepatic mRNA expression of TNF-α, IL-6 and
extensive proliferation of inflammatory and reticuloendothelial cells; however, anti-HMGB1 treatment did not decrease
gut mucosal permeability as compared to the sham IgG therapy at either 24 or 48 hrs.
Conclusion: HMGB1 neutralization is associated with bacterial translocation during APAP hepatotoxicity.
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Acetaminophen hepatotoxicity is the leading cause of
drug-induced acute liver failure (ALF) in the United
States and other industrialized nations [1]. ALF is associ-
ated with a high rate of infectious complications, most of
these infections are produced by gram negative enteric
bacteria [2]; however, the underlying mechanism is still
not clear. APAP overdose induces massive hepatocyte ne-
crosis [3-6] and necrotic tissue passively releases HMGB1
[7-9], a ubiquitous nuclear protein secreted by immuno-
competent cells, including monocytes, macrophages and* Correspondence: bobyangr@yahoo.com
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reproduction in any medium, provided the orneutrophils, is an important late inflammatory mediator
in sepsis [10]. HMGB1 also modulates the inflammatory
cascade in activated macrophages [11]. HMGB1 stimu-
lates macrophages to release TNF-α and IL-6, while
HMGB1neutralizing antibody can block TNF-α release
[11,12] and knocking-out HMGB1 receptor can reverse
IL-6 release [12]. HMGB1 contributes to liver injury in
ischemia-reperfusion [13] and exogenous HMGB1 in-
jection is able to induce gut hyper-permeability and BT
in normal mice [14]; therefore, it is possible that
HMGB1 mediates gut bacterial translocation in APAP
hepatotoxicity and we tested this hypothesis by using
anti-HMGB1 neutralizing antibody to treat APAP over-
dose for 24 or 48 hours in a murine model.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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All chemicals were purchased from Sigma-Aldrich Chem-
ical Co. (St. Louis, MO, USA) unless otherwise noted.
Polyclonal antibodies against HMGB1 were raised in
rabbits (Cocalico Biologicals, Reamstown, PA, USA),
and titers were determined by immunoblotting as previ-
ously described [15]. Anti–HMGB1 antibodies were
affinity-purified by using cyanogen bromide–activated
Sepharose beads following standard procedures. Neutra-
lizing activity of anti-HMGB1 was confirmed in HMGB1-
stimulated macrophage cultures by assay of TNF-α
release. In the presence of anti-HMGB1 antibody, neu-
tralizing antibody was defined as inhibiting > 80% of
HMGB1-induced TNF release. Sham IgG antibodies
were purified from non-immunized rabbit IgG.
Ethical considerations
This research protocol complied with the regulations re-
garding the care and use of experimental animals published
by the National Institutes of Health and was approved by
the Institutional Animal Use and Care Committee of the
University of Pittsburgh Medical School. Male C57Bl/6
mice weighing 20-25 g (Jackson Laboratories, Bar Harbor,
ME) were used in this study. The animals were maintained
at the University of Pittsburgh Animal Research Center
with a 12-hour light-dark cycle and free access to standard
laboratory feed and water. Animals were acclimatized for 7
days prior to being studied and fasted overnight prior to
the experiments.
Animal model and experimental groups
In the first experiment, acute liver injury (ALI) was in-
duced by a single dose of APAP (350 mg/kg dissolved in 1
mL sterile saline) administered by i.p. injection. 14 APAP
challenged mice were then randomized into the anti-
HMGB1 group (n = 6) and the sham IgG group (n = 8). 6
mice injected with saline not containing APAP served as
the control group. The animals in the anti-HMGB1 group
were given one administration (i.p.injection) of anti-
HMGB1 antibody (400 μg dissolved in 0.5 mL sterile
saline) 2 hrs after APAP injection. The same amount of
sham IgG was i.p. injected to the sham IgG group and
the control animals were injected with saline not con-
taining APAP at equivalent time points. 24 hrs after
APAP challenge, all surviving mice (2 mice died in the
sham IgG group) in each group were anesthetized with
sodium pentobarbital (90 mg/kg i.p.).
In the second experiment, ALI was induced the same
as above described. APAP injected mice were then ran-
domized into the anti-HMGB1 group (n = 10) and the
sham IgG group (n = 11). 6 mice injected with saline not
containing APAP served as the control group. The animals
in the anti-HMGB1 group were given 2 administrations of
anti-HMGB1 antibody (400 μg per dose dissolved in 0.5mL sterile saline): the first administration was given 2 hrs
after APAP injection, the second administration was given
24 hrs after the first administration of anti-HMGB1 anti-
body. The same amount of sham IgG was given to the
sham IgG group and the control animals were injected
with saline not containing APAP at equivalent time points.
48 hrs after APAP injection, all surviving mice (2 mice
died in the sham IgG group) in each group were anesthe-
tized with sodium pentobarbital (90 mg/kg i.p.).APAP bioactivation
The hepatic glutathione concentration was used to esti-
mate APAP bioactivation [16] in sham IgG or anti-
HMGB1 treated mice. Frozen liver samples (100 mg)
were homogenized in 1 mL of cold buffer containing
0.2 M 2-N-morpholino ethansulfonic acid, 50 mM
phosphate and 1 mM EDTA [pH 6.0]. Homogenates
were centrifuged and supernatants were collected.
Total hepatic glutathione concentration in the superna-
tants was measured using a commercially available kit
(Cayman Chemical Co., Ann Arbor, MI).Serum HMGB1 concentrations
Blood (1000 μL) was obtained by cardiac puncture; the
serum was collected and stored frozen at −80°C. HMGB1
was measured using an HMGB1 ELISA kit purchased from
Shino-Test Corporation (Japan, Kanagawa 229-0011).Serum aminotransferase measurements
Blood was obtained by cardiac puncture and serum levels
of ALT were measured at 37°C with a commercially avail-
able kit (Sigma Diagnostic).Intestinal mucosal permeability
Ileal mucosal permeability to the fluorescent tracer, FITC-
dextran with a molecular mass of 4000 Da (FD4), was de-
termined using an everted gut sac method, as previously
described [14,15,17]. In brief, everted gut sac were pre-
pared in ice-cold modified Krebs-Henseleit Bicarbonate
Buffer (KHBB) (pH = 7.4). One end of the gut segment
was everted onto a thin plastic rod. The resulting sac was
secured with another suture to the grooved tip of a 3-mL
plastic syringe containing KHBB. We gently distended the
sac by injecting 1.5 mL of KHBB. The sac was then sus-
pended for 30 minutes in a 50 mL beaker containing 40
mL of KHBB plus FD-4 (40 mg/mL). The solution in the
beaker was temperature-jacketed at 37°C and continuously
bubbled with a gas mixture containing 95% O2-5% CO2.
The FD4 concentration of the fluid in the beaker and
inside of the sac was determined spectroflurometrically,
and permeability was expressed as the mucosal-to-
serosal clearance of FD-4.
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ALF patients are prone to infection, sepsis and multiple
organ failure (MOF) [2]. In order to test the hypothesis
that HMGB1 mediates BT in APAP hepatotoxicity, BT to
the mesenteric lymph nodes (MLN) and to the liver was
determined as previously described [14,15,17]. Briefly, the
skin was cleaned with 10% povi-done-iodine. Using sterile
technique, the abdominal cavity was opened and the
viscera were exposed. The MLN complex and a piece of
liver tissue from the left lobe were removed, weighed,
and placed in a grinding tube containing 0.5 mL ice-cold
PBS. The MLN and liver tissue were homogenized with
glass grinders, and a 250-μL aliquot of the homogenate
was plated onto brain-heart infusion and MacConkey’s
agar (Becton Dickinson, Sparks, MD, USA). The plates
were examined 24 h later after being aerobically incubated
at 37°C. The colonies were counted and the results were
expressed as colony-forming units (CFU) per gram of
tissue.
Gut histopathology
A segment of terminal ileum tissue was fixed in 10% for-
malin buffer. The paraffin-embedded ileum was sectioned,
stained with hematoxylin and eosin (H&E) and examined
using light microscopy. Blind analysis was performed on
all samples to determine the degree of lesion per micro-
scopic field at a magnification of 200×. Five fields were
evaluated per tissue sample. Histological injury was graded
by pathologist using a standardized injury scoring system
according to Zhang et al. [18] with modifications as
follows: Grade 0, no injury; Grade 1, epithelial cells of
the villi became swollen, cell structure especially nuclei
became unclear; Grade 2, loss of mucosal epithelial lin-
ing of the villous tip; Grade 3, loss of mucosal epithelial
lining in area more than the villous tip.
Grade 4, less than 10% of the villi structure became
fragile to break; Grade 5, more than 30% of the villi be-
came fragile to break.
Real time RT-PCR
Hepatic mRNA levels of pro-regeneration cytokines TNF-
α, IL-6 were determined by real time RT-PCR as described
[19]. Total RNA was isolated with TRIzol reagent according
to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA). To determine the relative amount of cytokine mes-
senger RNA, amplification of sample complementary
DNA was monitored using the Smart Cycler (Cepheid,
Sunnyvale, CA) and the DNA fluorescent dye SYBR
Green (Molecular Probes, Eugene, OR). Primers were
designed using reported sequences in GenBank. Primer
sequences are as follows: interleukin (IL)-6: 5′GAGGA
TACCACTCCCAACAGACC, 3′ AAGTGCATCATCG
TTGTTCATACA; tumor necrosis factor (TNF-α): 5′
GGGACAGTGACCTGGACTGT, 3′ CTCCCTTTGCAGAACTCAGG; glyceraldehyde-3-phosphate dehydro-
genase: 5′ GTCTTCACCACCATGGAGAAG, 3′ CCAC
CTTCTTGATGTCATCAT. Primers were designed to
span at least one intron, if possible, to minimize risk of
genomic amplification. The specificity of the primers
was verified via analysis of polymerase chain reaction
(PCR) product with ethidium bromide-stained agarose
gel electrophoresis as well as direct sequencing of the
PCR product. All real-time PCR runs included a melting
curve analysis to assure the specificity of the product
with each PCR reaction.
Proliferating cell nuclear antigen (PCNA) staining
The liver plays an important role in the process of BT
[2] by virtue of its many phagocytic cells comprising
about 80% to 90% of the reticuloendothelial system func-
tion in the body [20]. Therefore, the PCNA imunohisto-
chemistry was carried out to confirm liver regeneration,
especially the proliferation of the non-parenchyma cells,
such as Kupffer cells, NK and other immune cells in the
liver, because these cells exert cellular defense functions
for the whole body but also for the liver itself and these
cells might also be severely damaged in the APAP hep-
atotoxicity. Therefore, sections from mouse liver follow-
ing APAP challenge were prepared and processed for
immunohistochemistry using PCNA staining kits from
Invitrogen (Camarillo, CA, USA) according to the man-
ufacturer’s instructions. In brief: A piece of liver tissue
from the left lobe was fixed in 10% formalin buffer.
Paraffin-embedded liver sections were dewaxed by treat-
ing the slides in 2 changes of xylene for 5 minutes each
and were rehydrated. Endogenous peroxidase activity
was quenched by using 0.3% H2O2 in PBS. The slides
were incubated with antigen retrieval solution at 89°C
for 10 minutes, then allow the solution to slowly cool
down to room temperature for 20 minutes. The slides
were incubated with ready-to-use blocking solution for
10 minutes and then incubated with biotinylated mono-
clonal anti-PCNA antibody (ready-to-use) for 1 hour.
After washing, sections were incubated with Strepta
vidin-Peroxidase (ready-to-use) for 10 minutes at room
temperature, followed by incubation with 3, 3′-diami-
nobenzidine (DAB) for 5 minutes. Slides were finally
counterstained with hematoxylin. Digital images of 5
high-power fields from each liver sample were obtained
in a random and blinded fashion, and the number of
PCNA-labeled nuclei was counted. The average num-
ber of PCNA-positive cells in each animal was used for
subsequent analysis.
Hepatocyte proliferation by 5-bromo-2-deoxyuridine
(BrdU) staining
We have found that the previous Invitrogen PCNA kits
stain non-parenchymal cells better than hepatocytes
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inflammatory cells in APAP overdose [22], suggesting
that the BrdU kits are more specific and suitable for he-
patocytes staining, and Invitrogen PCNA kits are more
specific for staining hepatic non-parenchymal cells, this
notion is further supported by the fact that on the stand-
ard positive control slide provided by the PCNA kits, a
large number of immune/inflammatory cells in the gut
lamina propria are also stained PCNA positive. Therefore,
we compared the two different staining kits in the same
experiment. Since at 24 h time point, the APAP challenged
C57/BL6 mice only showed occasional hepatocyte nuclei
labeled for 5-bromo-2-deoxyuridine (BrdU) [23], BrdU
test was performed only at 48 h time point in this study.
To evaluate hepatocyte regeneration, mice from the 48 h
groups were administered BrdU (50-mg/kg i.p. injection at
46 h time point) 2 hours before they were killed. A piece
of liver tissue from the left lobe was fixed in 10% formalin
buffer. Paraffin-embedded liver sections were prepared
and processed for immunohistochemistry using BrdU
in-situ staining kits from BD Pharmingen (San Jose, CA,
USA) according to the manufacturer’s instructions. In
brief: Paraffin-embedded liver sections were deparaffinized
by treating the slides in 2 changes of xylene for 5 minutes
each and were rehydrated. Endogenous peroxidase activity
was quenched by using 0.3% H2O2 in PBS. The slides were
incubated with antigen retrieval solution at 89°C for 10
minutes, then allow the solution to slowly cool down to
room temperature for 20 minutes. The slides were
incubated with an anti-BrdU antibody (1:10) for 1 hour.
After washing, sections were incubated with ready-to-use
Streptavidin-HRP for 30 minutes at room temperature,
followed by incubation with 3, 3′-diaminobenzidine
(DAB) for 5 minutes. Slides were finally counterstained
with hematoxylin. Digital images of 5 high-power fields
from each liver sample were obtained in a random and
blinded fashion, and the number of BrdU-labeled hep-
atocyte nuclei was counted. The average number of
BrdU-positive hepatocytes in each animal was used for
subsequent analysis.
Statistical methods
Data are presented as means ± SEM. Bacterial translocation
data CFU between groups were analyzed using Wilcoxon
U-test. Data are presented as means ± SEM. Continuous
data were analyzed using two-tailed student’s t-test or
analysis of variance followed by Fisher’s LSD test. The
statistical analysis was performed by GraphPad Prism
5.0 (La Jolla). Significance was accepted at the 5% level.
Results
APAP bioactivation
The hepatic glutathione concentration was used to esti-
mate APAP bioactivation in sham IgG or anti-HMGB1treated mice. Mice treated only with saline had 5.9 ± 0.4
μmol of glutathione/g liver tissue. 6 hours after APAP
injection (sham IgG or anti-HMGB1 antibody was injected
2 hours after APAP challenge), glutathione concentrations
were 0.69 ± 0.066 and 0.73 ± 0.08 μmol of glutathione/g
liver in mice treated with sham IgG and anti-HMGB1
neutralizing antibody, respectively. There was no signifi-
cant difference between the sham IgG group and the anti-
HMGB1 therapy group (n = 5 for each group).
Serum HMGB1 concentrations
24 hours and 48 hours after APAP challenge, serum
HMGB1 concentrations in the sham IgG groups and the
anti-HMGB1 groups were significantly increased as com-
pared to the control groups; the 24 h serum HMGB1 level
in the sham IgG group was significantly higher than the 48
h serum HMGB1 level in the sham IgG group; 24 h after
APAP injection, serum HMGB1 concentration in the anti-
HMGB1 group was significantly lower than that in the
sham IgG groups, and at 48 h time point, serum HMGB1
concentration in the anti-HMGB1 group was statistically
lower than that in the sham IgG group (Figure 1).
Bacterial translocation to MLN and the liver
The extent of bacterial translocation was measured in
our published APAP toxicity studies [21,24] (BT data
were not published) and the results showed that: when
i.p. injected into mice, APAP (300 mg/kg in 1 ml saline)
promoted BT as evidenced by greater numbers of viable
colony-forming units (CFU) compared with control mice
(injected with saline alone) when MLN homogenates were
cultured. The number of CFU (in the APAP injected mice)
began to increase at 6 h, reached the peak at 24 h, and
then the number of CFU decreased at 48 h, by 72 hours,
the bacterial translocation was not statistically greater than
that in the controls animals. Based on above information,
24 h and 48 h time points were selected to study BT in
this investigation. Our study showed that bacterial trans-
location (to MLN and the liver) was minimal in the con-
trol groups, however, there was extensive bacterial
translocation (to MLN and the liver) in the sham IgG
groups at both 24 h and 48 h time points, and about 85%
of BT in APAP injected mice could be reversed by anti-
HMGB1 treatment at both 24 h and 48 h (Figure 2). In
addition, the amount of BT was positively correlated with
serum HMGB1 levels (R2 = 0.95).
Gut mucosal permeability in APAP challenged mice
Compared to the control group, ileal mucosal permeability
was significantly increased in APAP challenged mice at
both 24 h and 48 h time points; compared to the
sham IgG treatment, the anti-HMGB1 therapy did
not reduce mucosal permeability at either 24 h or 48 h
(Figure 3).
Figure 1 Effect of treatment with anti-HMGB1 antibody or sham IgG on serum HMGB1 concentrations in acetaminophen (APAP)-
induced acute liver injury (ALI). ALI was induced in C57 BL/6 male mice with a single dose of APAP (350 mg/kg dissolved in 1 mL saline) by
intraperitoneal (i.p.) injection. 2 hrs after the APAP injection, 400 μg of anti-HMGB1 antibody in 0.5 mL saline was i.p. injected into mice in the
anti-HMGB1 group, the same amount of sham IgG or saline alone was given to the sham IgG group and the control animals at the equivalent
time points. The same amount of anti-HMGB1 or the sham IgG was repeated 24 hours after the first administration. Serum HMGB1 concentrations
were measured 24 hours after APAP injection from the anti-HMGB1 group, the sham IgG group and the control group (n = 6 for each group). 3
separate groups of mice were used to measure serum HMGB1 concentrations at 48 h time point from the anti-HMGB1 group (n = 10), the sham
IgG group (n = 9) and the control group (n = 6). Results are means ± SEM. *indicates p < 0.05 (analysis of variance followed by Fisher’s LSD test).
Figure 2 Effect of treatment with anti-HMGB1 antibody or sham IgG on bacterial translocation in mice with acetaminophen overdose.
A: Bacterial translocation (BT) to mesenteric lymph nodes (MLN) was assessed 24 and 48 hrs after APAP injection. B: Bacterial translocation to the
liver was assessed 24 and 48 hrs after APAP injection. The animal model and treatment were the same as described in Figure 1. Results are
means ± SEM. *indicates p < 0.05 (Wilcoxon U-test).
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Figure 3 Effect of treatment with anti-HMGB1 antibody or sham IgG on gut mucosal permeability in mice with acetaminophen
overdose. Ileal mucosal permeability was assessed 24 and 48 hrs after acetaminophen administration. The animal model and treatment were
the same as described in Figure 1. Results are means ± SEM. *indicates p < 0.05 (student’s T test).
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All mice subjected to APAP injection had significantly
increased histological injury scores at both 24 h and 48 h
time points as compared to the control animals (n = 6,
injury score = 0, p < 0.05). 24 h after APAP injection, the
injury score in the sham IgG group (4.3 ± 0.6, n = 6) was
not significantly different from the score in the anti-
HMGB1 group (4.1 ± 0.7, n = 6); at 48 h, the injury score
in the anti-HMGB1 therapy group (3.3 ± 0.5, n = 10) was
not significantly lower than that in the sham IgG group
(3.6 ± 0.4, n = 9). Results are means ± SEM (Figure 4).
Hepatic mRNA expression of TNF-α, IL-6
Real time RT-PCR was used to detect mRNA levels of
TNF-α, IL-6 in hepatic tissue, all of which have previ-
ously been implicated in priming hepatocyte regener-
ation of toxin-induced liver injury [25]. 24 hours after
APAP injection, compared to the control group, mRNA
levels of TNF-α and IL-6 were markedly increased in the
sham IgG treatment group (p< 0.05); blockade of HMGB1
significantly decreased hepatic mRNA levels of TNF-α,
IL-6 as compared to the sham IgG treatment (p < 0.05); 48
hours after APAP administration, compared to the control
group, sham IgG treatment statistically increased TNF-α
and IL-6 mRNA levels (p < 0.05); anti-HMGB1 therapy
significantly increased hepatic TNF-α, IL-6 mRNA levels
as compared to the sham IgG treatment (p < 0.05). Baseline
levels of all the cytokines remained low after saline injection
in the control group (Figure 5).
Hepatic proliferating cell nuclear antigen (PCNA) staining
We have shown that in APAP overdose, HMGB1 im-
pairs hepatocyte regeneration and blockade of HMGB1
improves hepatocyte regeneration and liver structure re-
covery seen in HE staining [22]. Our PCNA staining
showed that at 24 h time point, the PCNA staining in the
control and sham IgG groups was occasional (1.0 ± 0.1 per
high power field) (Figure 6A) and this proliferatingtendency was consistent with Javier Vaquero’s report
[23], in which BrdU staining was carried out to stain
proliferating hepatocytes; however, anti-HMGB1 group
consistently showed 14 ± 3 PCNA-positive nuclei per
high power field (Figure 6B) (n = 6 for each group), and
this number was significantly higher than that in the
sham IgG group (p < 0.05). At 48 hours, the total num-
ber of PCNA-labeled nuclei was 636 ± 45 per high
power field in the sham IgG group (Figure 6C, arrows
indicate those PCNA-positive nuclei at higher power
400×). Among the total number of the PCNA-positive
nuclei in the sham IgG group, 493 ± 33 were the
inflammatory cells that infiltrated in the necrotic area;
72 ± 8 were endothelial cells in the sinusoid; 41 ± 6 were
kupffer cells in the sinusoid; 30 ± 3 were other non-
parenchymal cells not recognized by nuclear staining. In
the anti-HMGB1 group at 48 h, the total number of
PCNA-labeled nuclei was 228 ± 14 per high power field
(Figure 6D). Among the total number of the PCNA-
positive cells in the anti-HMGB1 group, 70 ± 8 were
inflammatory cells mainly located in the necrotic area;
63 ± 8 were endothelial cells in the sinusoid; 44 ± 4
were kupffer cells in the sinusoid; 51 ± 6 were other
non-parenchymal cells not recognized by nuclear
staining. At 48 h, the total number of PCNA-positive
nuclei and the number of PCNA-positive inflammatory
cells in the sham IgG group were significantly larger than
that in the anti-HMGB1 group (p < 0.05). Our result was
consistent with Javier Vaquero’s report [23], in which
larger necrotic area had larger number of cell proliferation.
At 48 h, our result showed that the sham IgG group had
larger necrotic area (26.6 ± 3.5%) than the anti-HMGB1
group (4.2 ± 0.8%).
Liver injury and hepatic BrdU staining
24 hrs after APAP injection, anti-HMGB1 therapy did not
statistically decrease serum ALT/AST or significantly re-
duce necrosis as compared with the sham IgG group (n = 6
Figure 4 Effect of treatment with anti-HMGB1 antibody or sham IgG on gut mucosal injury in mice with acetaminophen overdose.
Hematoxylin-eosin staining of the terminal ileum was assessed 24 and 48 hours after acetaminophen administration. Animal model and
treatment were the same as described in Figure 1 (n = 6 for each group at 24 h; at 48 h time point, n = 9 for the sham IgG group and
n = 10 for the anti-HMGB1 group. A = control, B = sham IgG at 24 h, C = anti-HMGB1 at 24 h, D = sham IgG at 48 h, E = anti-HMGB1 at 48 h,
magnification = 200× for each photo). Typical picture is shown. Arrow indicates the loss of mucosal epithelial line of the villi.
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the sham IgG treatment showed evident hepatocyte regen-
eration at 24 h (published in reference [22]). 48 hrs after
APAP challenge, the sham IgG treated mice showed sig-
nificantly larger hepatic necrotic area than the anti-
HMGB1 treated animals and blockade of HMGB1
significantly decreased serum transaminases (ALT and
AST) (published in reference [22]). Similarly, in a new
48 h BrdU experiment, sham IgG treated mice demon-
strated 26.6 ± 3.5% necrotic area, which was signifi-
cantly larger than that in the anti-HMGB1 group (4.2 ±
0.8%); the sham IgG group also had significantly higher
serum ALT (480 ± 35 U/L) than that in the anti-
HMGB1 group (148 ± 17 U/L, results are means ± SEM,
n = 6 for each group).
The hepatocyte proliferation was assessed by BrdU
immunohistological staining. At 48 hours, as compared
with the control group (the number of BrdU-positive cells
in the control group was 1.0 ± 0.1 per high power field),
the number of BrdU-labeled nuclei (per high power) was
significantly increased in both sham IgG (82 ± 8, Figure 6E)
and anti-HMGB1 (18 ± 2, Figure 6F) groups (results are
means ± SEM, n = 6 for each group), although to a statisti-
cally lesser extent in the anti-HMGB1 treated mice, our
result was consistent with Javier Vaquero’s report [23] in
which after 48 h, the extent of hepatic BrdU expression,however, depended mainly on the extent of damage,
because it was significantly correlated with the area of
hepatocyte necrosis for each mouse [23].
Discussion
HMGB1 is a well-known late inflammatory mediator in
sepsis [10] and it can be released readily from necrotic
or damaged cells to serve as a signal for inflammation
[26]. In APAP overdose, massive necrotic hepatocytes
release HMGB1 [9], HMGB1 impairs hepatocyte regen-
eration and blockade of HMGB1 improves hepatocyte
regeneration and liver structure recovery [22]. In this
study, our data showed that larger hepatic necrosis was
associated with higher serum HMGB1 levels and larger
number of BT. At 48 h time point, compared to the
sham IgG group, the anti-HMGB1 group had smaller
necrotic area, the smaller necrosis likely released less
HMGB1 to mediate less bacteria translocation.
The liver not only filters the blood returning from the
intestines to remove noxious agents, but also plays an im-
portant role in the process of BT [2] by virtue of its many
phagocytic cells comprising about 80% to 90% of the reticu-
loendothelial system function in the body [20]. Additionally,
the liver produces acute phase proteins, which act as prote-
ase inhibitor or opsonins, the liver actively participates in
the body defense mechanisms against infections [27].
Figure 5 Effect of treatment with anti-HMGB1 or sham IgG on the mRNA expression of hepatic TNF-α and IL-6 in mice challenged with
acetaminophen overdose. 24 and 48 hours after APAP administration, relative messenger RNA levels of (A) TNF-α and (B) IL-6 were detected
using real-time PCR. Animal model and treatment were the same as described in Figure 1. Baseline (control) levels of cytokines were measured 24 and
48 hrs after saline injection. *indicates p < 0.05 (analysis of variance followed by Fisher’s LSD test). GAPDH = glyceraldehydes-3-phosp dehydrogenase.
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toxic insult [28,29]. Regeneration ensures the replace-
ment of necrotic cells and the full recovery of organ
function. Since hepatocytes are mostly in a quiescent
state (G0), the regeneration process requires entry into
the highly regulated cell cycle [25]. The first step of this
process is to prime hepatocytes by cytokines such as
TNF-α and IL-6 [25], which makes cells more responsive
to growth factors [25]. In current investigation, our PCR
data also demonstrated that anti-HMGB1 antibody ther-
apy significantly increased the expression of regeneration-
promoting transcripts TNF-α and IL-6 in APAP-treated
liver tissue at 48 h time point, suggesting that blockade of
HMGB1 likely facilitates activation of TNF-α, IL-6 path-
way to restore hepatic structure. Our study also showed
that at 24 h, the PCNA staining in the control and sham
IgG groups was occasional (1.0 ± 0.1 per high power field),
however, anti-HMGB1 group consistently showed 14 ± 3
PCNA-positive nuclei per high power field, and these cells
were not hepatocytes, this is not consistent with the re-
sults from HE staining in which anti-HMGB1 treatment
shows evident hepatocyte regeneration while the sham
IgG therapy does not [22], the underlying mechanism
is unknown. 48 h after APAP injection, the number of
PCNA-labeled nuclei was significantly increased in both
the sham IgG and the anti-HMGB1 groups, most of thePCNA-positive cells were inflammatory cells and other
non-parencymal cells, suggesting that the hepatic immune
function is likely to be compromised to block bacterial
translocation through the liver. 48 h after APAP adminis-
tration, the sham IgG group still had larger hepatic necro-
sis; in contrast, the anti-HMGB1 treatment showed better
recovered liver structure, reduced hepatic bacterial
translocation and significantly increased hepatic TNF-
α and IL-6 mRNA expression at late phase, suggest
that it is possible that liver immune system in the anti-
HMGB1 therapy group is recovered better than the
sham IgG group. At 48 h, even though the number of
PCNA-positive non-parenchymal cells in the sham IgG
group was larger than that in the anti-HMGB1 therapy
group, the larger number of PCNA positive cells at late
phase might indicate larger liver necrotic area (this is
consistent with Javier Vaquero’s report [23]) in the
sham IgG group than the anti-HMGB1 group, these
PCNA-positive cells are in the stage of proliferation
and they are immature to function normally; in con-
trast, at late phase, the smaller number of PCNA-
positive cells in the anti-HMGB1 group might indicate
less liver injury in the anti-HMGB1 group, and the im-
mune system in this group might be more closer to
normal than the sham IgG group, resultantly, anti-
HMGB1 treatment decreased BT to the liver because
Figure 6 Effect of treatment with anti-HMGB1 antibody or sham IgG on hepatic proliferation in mice challenged with acetaminophen
overdose. PCNA staining was assessed 24 and 48 hours after acetaminophen administration. Animal model and treatment were the same as
described in Figure 1 (n = 6 for each group at 24 h time point, n = 9-10 for each group at 48 h. A= sham IgG at 24 h, B= anti-HMGB1 at 24 h, C= sham
IgG at 48 h, D= anti-HMGB1 at 48 h, arrows indicate those PCNA-positive nuclei at high power 400×). Figure 6E and F: Effect of treatment with sham or
anti-HMGB1 antibodies on hepatocyte regeneration in acetaminophen injected mice. Animal model and treatment were the same as the
48 h experiment described in Figure 1 except that mice from the 48 h groups were administered 5-bromo-2-deoxyuridine (BrdU, 50-mg/kg
i.p. injection at 46 h time point). BrdU staining was assessed at 48 h (n = 6 for each group, E = sham IgG at 48 h, F = anti-HMGB1 at 48 h,
magnification = 200× for A, B, C, D, E and F). A typical picture is shown.
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tem are two important factors to process BT in the liver.
24 h after APAP injection, as compared to the normal
control group, sham IgG treatment significantly in-
creased TNF-α and IL-6 mRNA levels and the enhanced
TNF-α and IL-6 mRNA expression was associated with
large necrosis without evident regeneration [22]; in con-
trast, anti-HMGB1 therapy instead of the sham IgG treat-
ment markedly decreased these two cytokines’ mRNA
expression and improved hepatocyte regeneration at early
phase [22], this indicates that TNF-α and IL-6 are pro-
inflammatory cytokines at early phase and their mRNA
expressions are modulated by HMGB1, this result is sup-
ported by the following two reports [11,12] in which
HMGB1 stimulates macrophages to release TNF-α and
IL-6, neutralizing HMGB1 blocks TNF-α release [11,12]
and knocking-out HMGB1 receptor reverses IL-6 release
[12]. TNF-α and IL-6 are well known as important pro-
inflammatory cytokines; however, their roles in APAP
overdose are controversial. Knocking out the TNF-α re-
ceptor reduces hepatocyte proliferation in APAP toxicity
[30], and IL-6 knockout mice are more susceptible to
APAP-induced liver injury than the wild type mice [31],suggesting that IL-6 may protect liver from injury. In
current study at 48 h, anti-HMGB1 treatment instead of
the sham IgG therapy markedly enhanced hepatic TNF-α
and IL-6 mRNA levels, the increase in TNF-α and IL-6 at
later phase could be due to the fact that macrophages (the
classically activated M1 and alternatively activated M2
populations) are proliferating and/or migrating into the
liver [32,33], and the M1 subset macrophages might play
hepatotoxic role at early stage of ALF, while the M2 subset
macrophages likely play hepatoprotective role at late phase
of ALF [32]; it is also possible that hepatocytes could also
produce these cytokines and their regeneration can be
responsible for this increase. The increased TNF-α and
IL-6 expression at late phase was associated with better
recovered hepatic structure, these results indicate that in-
flammation might play different roles at different phases
in APAP overdose: inflammation likely contributes to liver
injury at early phase but also likely improves hepatocyte
regeneration and liver recovery at late phase. This notion
is supported by the following APAP overdose studies
[21,24,34] in which Ringer’s lactate, the pro-inflammatory
solution, increases serum TNF-α and improves liver re-
covery at late phase while the anti-inflammatory agent
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impairs hepatic regeneration at late phase; kupffer cells
(KC) are important source of TNF-α and IL-6 and play
important roles in inflammation, and KC depletion con-
fers protection at early time points after APAP treatment
but can lead to more severe injury at later time point [34].
Gut mucosal barrier plays an important role in BT; the
intact gut mucosal barrier is essential to prevent intes-
tinal bacterial translocation. When the integrity of intes-
tinal mucosa is impaired, it would be easier for gut
luminal bacteria to adhere to the injured mucosa to fa-
cilitate BT. In current study, as compared to the control
group, the gut mucosal permeability was significantly in-
creased in the APAP challenged mice at both 24 h and
48 h, the mucosal permeability in the sham IgG treat-
ment groups (both 24 h and 48 h) was not significantly
higher than that in the anti-HMMGB1 therapy groups;
however, as compared to the sham IgG treatment groups,
HMGB1 neutralizing antibody treatment blocked about
85% of BT at both early and late time points, the results
indicate that BT is likely a HMGB1-mediated (at least
partly) active procedure, in which, except the impaired
mucosal integrity, HMGB1 is also needed and it is
unlikely that gut luminal bacteria passively translocate
via the damaged mucosal paracellular tight junction,
further investigation is needed to clarify the underlying
mechanism.
Gut permeability and bacterial translocation are posi-
tively correlated in hemorrhagic shock model [17] and
endotoxemic model [14,35]; however, emerging evidence
shows that gut permeability and bacterial translocation
could be disassociated in the following two animal models
[36,37]: in an alcoholic liver injury model [36], ethyl pyru-
vate (EP), an potent anti-inflammatory agent, which has
been reported to be able to reduce gut bacterial transloca-
tion but it does not decrease gut permeability; in a severe
acute pancreatitis model [37], EP inhibits gut bacterial
translocation but does not reduce ileal mucosal permea-
bility. The underlying mechanism is still not clear; more
studies are needed to clarify this issue.
Collectively, our results support the notion that HMGB1
is an important factor, which links the APAP hepato-
toxicity and gut bacterial translocation; once the enteric
bacteria enter the systemic circulation, it likely triggers the
systemic inflammatory response (SIRS) and leads to sepsis,
MOF [38] and death in APAP hepatotoxicity.Conclusion
HMGB1 neutralization is associated with bacterial
translocation during acetaminophen hepatotoxicity;
blockade of HMGB1 may present a novel therapy to
prevent multiple organ failure from gut bacterial
translocation in APAP overdose.Abbreviations
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